Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

被引：1
|
作者：
Rueda, Antonio [1 ]
Calvo, Virginia [2 ]
Casanova, Maria [1 ]
Rodriguez-Abreu, Delvys [3 ]
Aguiar, David [4 ]
Llanos, Marta [5 ]
Alvarez, Ruth [6 ]
Martinez-Banaclocha, Natividad [7 ]
Alfaro, Jesus [8 ]
Quero, Cristina [9 ]
Blasco, Ana [10 ]
de la Cruz Merino, Luis [11 ]
Herrero, Joaquin [12 ]
Garcia-Arroyo, Francisco R. [13 ]
Provencio, Mariano [2 ]
机构：
[1] Hosp Costa Sol, Marbella, Spain
[2] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
[3] Hosp Insular, Las Palmas Gran Canaria, Las Palmas, Spain
[4] Hosp Dr Negrin, Las Palmas Gran Canaria, Las Palmas, Spain
[5] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[6] Hosp Virgen Salud, Toledo, Spain
[7] Hosp Gen Univ Elche, Alicante, Spain
[8] Oncologikoa, Donostia San Sebastian, Spain
[9] Hosp Univ Gen & Virgen Victoria, Malaga, Spain
[10] Hosp Gen Univ, Valencia, Spain
[11] Hosp Virgen Macarena, Seville, Spain
[12] Hosp Gen Univ Alicante, Alicante, Spain
[13] Complexo Hosp Univ Pontevedra, Pontevedra, Spain
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 06期
关键词：
NON-HODGKIN-LYMPHOMA; INDOLENT B-CELL; PLUS RITUXIMAB; MANTLE-CELL; 1ST-LINE TREATMENT; OPEN-LABEL; RELAPSED INDOLENT; MULTICENTER; OBINUTUZUMAB; THERAPY;
D O I：
10.1080/10428194.2018.1542147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1576 / 1579
页数：4
相关论文
共 50 条
  • [21] Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial
    Javier Penalver, Francisco
    Antonio Marquez, Jose
    Duran, Soledad
    Giraldo, Pilar
    Montalban, Carlos
    Jose Ramirez, Marya
    Manuel Sancho, Juan
    Jose Terol, Maria
    Javier Capote, Francisco
    Gutierrez, Antonio
    Sanchez, Blanca
    Canales, Miguel
    Dolores Caballero, Maria
    BLOOD, 2012, 120 (21)
  • [22] RESPONSE-ADAPTED TREATMENT WITH RITUXIMAB/BENDAMUSTINE/MITOXANTRONE/DEXAMETHASONE AND MAINTENANCE THERAPY WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA IN RELAPSE OR REFRACTORY TO FIRST-LINE TREATMENT WITH IMMUNOCHEMOTHERAPY. RBMDGELTAMO08
    Francisco Javier, Penalver Parraga
    Jose Antonio, Marquez Navarro
    Nieto Soledad, Duran
    Castellano Pilar, Giraldo
    Sanz Carlos, Montalban
    Maria Jose, Ramirez Sanchez
    Juan Manuel, Sancho Cia
    Maria Jose, Terol Castera
    Francisco Javier, Capote Huelva
    Garcia Antonio, Gutierrez
    Gonzalez Blanca, Sanchez
    Silvestre Antonio, Salar
    Albendea Miguel, Canales
    Maria Dolores, Caballero Barrigon
    HAEMATOLOGICA, 2016, 101 : 9 - 9
  • [23] Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group
    Provencio, Mariano
    Cruz Mora, Miguel A.
    Gomez-Codina, Jose
    Quero Blanco, Cristina
    Llanos, Marta
    Garcia-Arroyo, Francisco R.
    de la Cruz, Luis
    Guma Padro, Josep
    Delgado Perez, Juan R.
    Sanchez, Antonio
    Alvarez Cabellos, Ruth
    Rueda, Antonio
    LEUKEMIA & LYMPHOMA, 2014, 55 (01) : 51 - 55
  • [24] Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial
    Sarkozy, Clementine
    Trneny, Marek
    Xerri, Luc
    Wickham, Nick
    Feugier, Pierre
    Leppa, Sirpa
    Brice, Pauline
    Soubeyran, Pierre
    Da Silva, Maria Gomes
    Mounier, Christiane
    Offner, Fritz
    Dupuis, Jehan
    Caballero, Dolores
    Canioni, Danielle
    Paula, Marlton
    Delarue, Richard
    Zachee, Pierre
    Seymour, John
    Salles, Gilles
    Tilly, Herve
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (22) : 2575 - 2582
  • [25] Phase II study of PEG-Intron in combination with chemotherapy for the treatment of first line patients with follicular lymphoma who need to be treated.
    Saba, CE
    Brice, P
    Haioun, C
    Feugier, P
    Bauduer, F
    Salles, B
    Du Manoir-Baumgarten, C
    Blanc, M
    Kulekci, C
    Coiffier, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 575S - 575S
  • [26] Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403)
    Portell, Craig A.
    Jegede, Opeyemi
    Wagner-Johnston, Nina D.
    Nowakowski, Grzegorz S.
    Fletcher, Christopher D.
    Cohen, Jonathon B.
    David, Kevin A.
    Khan, Nadia
    Rosenstein, Lori J.
    Kahl, Brad S.
    BLOOD, 2021, 138
  • [27] Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group
    Pectasides, D
    Aravantinos, G
    Kalofonos, H
    Kiamouris, C
    Bafaloukos, D
    Xiros, N
    Nicolaides, C
    Visvikis, A
    Dimopoulos, MA
    ANNALS OF ONCOLOGY, 2001, 12 (10) : 1417 - 1422
  • [28] Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
    Kersten, Marie Jose
    Dreyling, Martin
    Linton, Kim M.
    Chitu, Dana
    Tonino, Sanne
    Kap, Marcel
    Liu, Roberto D.
    Chamuleau, Martine E. D.
    Visser, Hein P. J.
    De Jongh, Eva
    Marijt, Erik Waf
    Leijs, Maria B. L.
    Bilgin, Yavuz M.
    Duerig, Jan
    McKay, Pamela
    Snijders, Tjeerd J. F.
    Pettitt, Andrew
    Minnema, Monique C.
    Prange-Krex, Gabriele
    Cuijpers, Maria
    Boehmer, Lara H.
    Tick, Lidwine W.
    Florschuetz, Axel
    Silbermann, Matthijs
    Fijnheer, Rob
    Beeker, Aart
    Tolboom, Nelleke
    Mitea, Cristina
    Arens, Anne I. J.
    Zwezerijnen, Gerben J. C.
    Klapper, Wolfram
    Coupland, Sarah E.
    de Jong, Daphne
    Doorduijn, Jeanette K.
    Zijlstra, Josee M.
    BLOOD, 2022, 140 : 2283 - 2285
  • [29] Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P
    Dizon, Don S.
    Blessing, John A.
    McMeekin, D. Scott
    Sharma, Sudarshan K.
    DiSilvestro, Paul
    Alvarez, Ronald D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3104 - 3108
  • [30] Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study
    Iannitto, Emilio
    Bellei, Monica
    Ferreri, Andres J. M.
    Marcheselli, Luigi
    Cesaretti, Marina
    Haioun, Corinne
    Mancuso, Salvatrice
    Bouabdallah, Krimo
    Gressin, Remy
    Tripodo, Claudio
    Traverse-Glehen, Alexandra
    Baseggio, Lucile
    Zupo, Simonetta
    Stelitano, Caterina
    Castagnari, Barbara
    Patti, Caterina
    Merli, Francesco
    Liberati, Anna Marina
    Merli, Michele
    Gini, Guido
    Cabras, Maria Giuseppina
    Dupuis, Jehan
    Re, Francesca
    Zucca, Emanuele
    Federico, Massimo
    Thieblemont, Catherine
    BLOOD, 2017, 130
12345